This webinar on November 21st examined how biomarkers are used to define “PD-L1” positive patients around the globe and in resource limited settings. It provided a forum for physicians to discuss their experience assessing different criteria, as well as the solutions that were implemented to overcome specific challenges. Additionally, this topic reviewed the global availability of different platforms/clones and tumor mutational burden (TMB). View the webinar for FREE on-demand HERE.
#Webinar#Policy